Clincial Trials- Myelodysplastic Syndrome

 MDS  "Randomized Phase III Trial Comparing the Frequency of Major Erythroid
Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in
Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia **Lenalidomide training required for each enrolling study physician. (E2905)" 

Marcia Grafe                                 402-483-2827            


Rebecca Hadenfeldt, RN, BSN

P: 308-398-6783

F: 309-398-3219


 Lincoln Medical Education Partnership Lincoln, NE; Saint Francis Cancer Treatment Center, Grand Island, NE
 MDS A Phase III, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndrome  III  Rose Hoyt  The Nebraska Medical Center, Omaha NE

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508 (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software